Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Orgenesis Inc. (ORGS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6900-0.0800 (-4.52%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.7700
Open1.7400
Bid1.5000 x 1200
Ask1.7400 x 1000
Day's Range1.6700 - 1.7900
52 Week Range1.5700 - 5.4300
Volume58,995
Avg. Volume39,590
Market Cap43.172M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8960
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ORGS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Orgenesis Inc.
    Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

    Secures Funding from Metalmark Capital Partners to Drive Growth Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022. Vered Caplan, CEO of Orgenesis, said, “We are progressing with our transit

  • GlobeNewswire

    Orgenesis Schedules Second Quarter 2022 Business Update Conference Call

    GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 fo

  • GlobeNewswire

    Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

    GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today provided a business update for first quarter ended March 31, 2022. Recent highlights: Expanded POCare with Johns Hopkins University through creation of the Maryland Center for Cell Therapy ManufacturingReached milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madr

Advertisement
Advertisement